MarketCap
Facebook
X
Telegram
Anixa Biosciences Income Statement 2025-2009 | ANIX
Brief overview of financial results at Anixa Biosciences
The figures are compared over a five-year interval. According to figures from Anixa Biosciences, revenue changed from $250 thousand to $210 thousand over five years. Across the full period, sales moved by −16%; the average annual rate was −3.4%. Revenue ended the period on a sustained downward trend.
The five-year EBITDA result moved by −25.1%: from −11.1 million dollars to −13.8 million dollars. There was no major divergence between EBITDA and revenue. At the operating-margin level, the figure shifted from −4421% to −6586.2%. A lower EBITDA share weakens the quality of the result.
Comparing the endpoints shows a move from −11.6 million dollars to −12.6 million dollars. The negative result deepened, showing weaker final efficiency.
Market capitalization changed from 75.8 million dollars to 70.8 thousand dollars (−99.9%). Market value lagged the financial performance.
Financial takeaway
The current trajectory does not yet confirm a sustainable recovery. The weaker side of the profile includes declining capitalization, a softer top-line trend and a declining EBITDA margin. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
104 K | 70.8 K | 151 K | 137 K | 60.1 M | 58.7 M | 75.8 M | 69.1 M | 30.5 M | 54.7 M | 27 M | 40.7 M | 45.4 M | 39.9 M | 23.8 M | - | - |
Shares |
32.5 K | 31.9 K | 31 K | 30.4 K | 30.1 M | 22.2 M | 19.8 M | 17.6 M | 12.2 M | 9.6 M | 9.63 M | 9.57 M | 8.64 M | 7.98 M | 7.33 M | 154 M | - |
Historical Prices |
3.19 | 2.22 | 4.87 | 4.52 | 2.97 | 3.07 | 3.28 | 3.94 | 2.36 | 5.4 | 3.01 | 2.75 | 4.75 | 4.5 | 2.75 | - | - |
Net Income |
-10.9 M | -12.6 M | -9.81 M | -13.6 M | -13 M | -10.1 M | -11.6 M | -14 M | -5.01 M | -5.02 M | -1.38 M | -9.61 M | -10.1 M | -4.25 M | -7.38 M | -5.18 M | - |
Revenue |
- | 210 K | 210 K | - | 512 K | - | 250 K | 1.11 M | 362 K | 300 K | 9.26 M | 3.67 M | 389 K | 947 K | 1 M | - | - |
Gross Profit |
- | - | - | - | - | - | 83.8 K | 344 K | 258 K | 82.6 K | 5.61 M | 1.68 M | 72.2 K | 943 K | 969 K | - | - |
Operating Income |
-11.7 M | -13.8 M | -11 M | -13.9 M | -13.1 M | -9.98 M | -11.9 M | -14.3 M | -6.08 M | -4.51 M | -945 K | -5.04 M | -7.92 M | -4.13 M | -5.03 M | -5.25 M | - |
Interest Expense |
- | - | - | - | - | - | - | - | 500 K | 520 K | 452 K | 1.26 M | 1.11 M | 7.66 K | - | - | - |
EBITDA |
-11.7 M | -13.8 M | -11 M | -13.9 M | -13.1 M | -9.94 M | -11.1 M | -13.4 M | -5.75 M | -4.18 M | -619 K | -4.73 M | -7.92 M | -4.13 M | -5.02 M | -5.24 M | - |
Operating Expenses |
- | - | - | - | - | 9.98 M | 11.6 M | 14.1 M | 6.33 M | 4.59 M | 6.55 M | 6.72 M | 7.99 M | 5.08 M | 6 M | - | - |
General and Administrative Expenses |
6.63 M | 7.44 M | 6.29 M | 7.17 M | 7.07 M | 5.6 M | 5.66 M | 6.91 M | 4.41 M | 2.71 M | 6.23 M | 6.41 M | 7.99 M | - | - | 2.89 M | - |
All numbers in USD currency
Quarterly Income Statement Anixa Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
33.6 M | 33.2 M | 33.2 M | 33 M | 32.5 M | 32.2 M | 32.2 M | 32.2 M | 32.1 M | 31.9 M | 31.4 K | 31.1 M | 31 K | 30.9 K | 30.9 K | 30.9 M | 30.5 K | 30.2 M | 25.2 M | 30.1 M | 30.5 M | 28.7 M | 20.7 M | 21.7 M | 23.2 M | 21.2 M | 19.2 M | 19.6 M | 20.1 M | 19.6 M | 16.6 M | 17.3 M | 18.4 M | 16.7 M | 8.76 M | 11 M | 14.6 M | 9.73 M | 8.73 M | 8.74 M | 8.75 M | 8.74 M | 8.79 M | 8.77 M | 8.76 M | 8.77 M | 210 M | 8.62 M | 8.93 M | 213 M | 185 M | 193 M | 202 M | 192 M | 178 M | 181 M | 183 M | 181 M | - | 164 M | 171 M | 166 M |
Net Income |
-2.52 M | -2.56 M | -2.56 M | - | -2.26 M | -2.79 M | -3.18 M | - | -3.28 M | -3.14 M | -3.26 M | - | -2.51 M | -2.29 M | -2.32 M | -10.1 M | -2.75 M | -3.54 M | -2.21 M | -8.94 M | -4.33 M | -2.4 M | -2.59 M | -7.79 M | -2.56 M | -2.64 M | -4.97 M | -9.56 M | -2.14 M | -2.57 M | -1.84 M | -8.85 M | -5.48 M | -1.38 M | -3.6 M | -3.22 M | -1.79 M | 160 K | -1.59 M | -3.97 M | -1.1 M | -1.27 M | 3.75 M | -86.6 K | -1.6 M | -2.24 M | -3.61 M | -6.45 M | 411 K | -3.25 M | -2.09 M | -7.15 M | -2.58 M | -2.48 M | -886 K | -1.86 M | -629 K | -877 K | -1.53 M | -2.79 M | -1.77 M | -1.29 M |
Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | 210 K | 513 K | - | - | - | 512 K | 513 K | 513 K | - | - | - | - | - | - | 250 K | 250 K | 250 K | - | 1.11 M | 362 K | 750 K | - | 362 K | 362 K | - | - | 100 K | 100 K | - | 9.14 M | 9.26 M | 95 K | 25 K | - | 2.29 M | 1.19 M | 1.1 M | 2.13 K | - | - | - | 449 K | 350 | 249 K | 248 K | 17 K | 449 K | 450 K | 86.9 K |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 595 K | - | - | 2.84 M | 1.09 M | - |
Operating Income |
-2.65 M | -2.72 M | -2.72 M | - | -2.44 M | -3 M | -3.39 M | - | -3.59 M | -3.47 M | -3.61 M | - | -2.84 M | -2.56 M | -2.56 M | -10.3 M | -2.8 M | -3.59 M | -2.23 M | -9.06 M | -4.39 M | -2.44 M | -2.63 M | -7.74 M | -2.44 M | -2.67 M | -4.98 M | -9.76 M | -2.18 M | -2.59 M | -1.87 M | -8.88 M | -5.61 M | -1.4 M | -1.39 M | -4.34 M | -1.73 M | -1.21 M | -1.47 M | -3.6 M | -975 K | -1.15 M | 3.86 M | 233 K | -1.49 M | -2.13 M | -1.96 M | -3.48 M | -160 K | -1.36 M | -2.07 M | -6.14 M | -2.22 M | -1.85 M | -887 K | -2.41 M | -643 K | -878 K | -1.53 M | -4.02 M | -1.21 M | -1.29 M |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.27 K | - | - | 53.8 K | 18.4 K | - | - | - | - | - | 195 K | 443 K | 71.7 K | 176 K | 124 K | 383 K | 132 K | 127 K | 109 K | 334 K | 116 K | 109 K | 379 K | 1.08 M | 281 K | 422 K | 22.2 K | 983 K | 125 K | 835 K | - | - | - | - | - | - | - | - |
EBITDA |
-2.65 M | -2.72 M | - | - | - | - | - | - | - | - | - | - | - | - | -2.56 M | -10.3 M | -2.8 M | -3.59 M | -2.23 M | -9.06 M | -4.39 M | -2.44 M | -2.61 M | -7.7 M | -2.41 M | -2.67 M | -4.98 M | -9.73 M | -2.17 M | -2.47 M | -1.87 M | -8.87 M | -5.6 M | -1.32 M | -1.38 M | -4.31 M | -1.71 M | -1.13 M | -1.47 M | -3.57 M | -961 K | -1.07 M | 3.86 M | 477 K | -1.41 M | -2.05 M | -1.89 M | -3.25 M | -78.3 K | -1.27 M | -2.07 M | -6.14 M | -2.22 M | -1.85 M | -885 K | -2.41 M | -643 K | -878 K | -1.52 M | -4.02 M | -1.2 M | -1.29 M |
General and Administrative Expenses |
1.39 M | 1.61 M | 1.61 M | - | 1.38 M | 1.68 M | 1.83 M | - | 1.67 M | 1.82 M | 2.26 M | - | 1.76 M | 1.61 M | 1.49 M | 5.25 M | 1.35 M | 1.85 M | 1.53 M | 5.17 M | 2.22 M | 1.42 M | 1.14 M | 3.76 M | 1.18 M | 1.44 M | 2.07 M | 4.41 M | 1.06 M | 1.28 M | 990 K | 4.6 M | 2.7 M | 909 K | 860 K | 3.07 M | 1.51 M | 699 K | 873 K | 2.16 M | 631 K | 659 K | 1.77 M | 5.15 M | 1.42 M | 1.96 M | 1.86 M | 4.81 M | 1.1 M | 1.84 M | 2.07 M | 6.12 M | 2.2 M | 1.84 M | 686 K | 1.64 M | 434 K | 522 K | 761 K | 2.15 M | 775 K | 618 K |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Anixa Biosciences (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Niderland
Germany
Israel
Britain
Canada
China
Australia
Schweiz
Irlanda
